MarketPulse

cardiovascular disease

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Coagulation Analyzer Market Eyes $7.87B Valuation by 2035 on Blood Disorder Surge

Coagulation analyzer market projected to reach $7.87B by 2035 from $4.60B in 2025, driven by rising blood disorders and surgical volumes.
ABTDHRSMMNYcardiovascular diseasehealthcare diagnostics
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics' Gene-Editing Pipeline Targets $100B+ Cardiovascular Market

CRISPR Therapeutics advances promising pipeline candidates CTX310 and CTX320 targeting cardiovascular disease, though company remains unprofitable with minimal revenue.
CRSPgene therapyType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Newamsterdam Pharma Company N.V.

NewAmsterdam Pharma Awards Inducement Grants to New Hires Under Nasdaq Rules

NewAmsterdam Pharma grants 15,000 options and 3,200 RSUs to two new executives, complying with Nasdaq listing regulations.
NAMSNAMSWrestricted stock unitsvesting schedule
BenzingaBenzinga··Usa News Group

Five AI Leaders Transform Cardiac Diagnostics, Expanding Access to Remote Communities

Five AI companies advance decentralized cardiac diagnostics through partnerships expanding access to remote communities and strengthening clinical evidence bases.
GEHCHTFLBEATBEATWHYPR+1clinical validationcardiovascular disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kestra Medical's 2025 IPO Nabs GeekWire 'Deal of the Year' Finalist Spot

Kestra Medical Technologies ($KMTS) named finalist for GeekWire's 2026 Deal of the Year award, recognizing its successful 2025 IPO launch in wearable cardiac care.
KMTScardiovascular diseaseinitial public offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioCardia to Unveil 2025 Results, Corporate Strategy on March 24 Call

BioCardia scheduled conference call for March 24, 2026 to report full-year 2025 financial results and provide corporate update.
BCDAfinancial resultsconference call
BenzingaBenzinga··Vandana Singh

Tenaya Therapeutics Surges 31% on Alnylam Cardiovascular Research Deal

Tenaya Therapeutics surges 31% after partnering with Alnylam on cardiovascular genetic targets, securing $10M upfront and $1.13B in potential milestone payments.
TNYAALNYgene therapycardiovascular disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Seer, Inc.

Seer Showcases Proteograph Platform at US HUPO 2026 Conference

Seer presents its Proteograph platform at US HUPO 2026, showcasing proteomics research across cardiovascular, neurodegenerative, aging, and oncology applications using minimal sample volumes.
SEERproteomicsProteograph Product Suite
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Pulmonary Artery Catheter Market Projected to Expand 60% Through 2035

Pulmonary artery catheter market projected to grow from $1.23B to $1.97B by 2035, driven by rising cardiovascular disease and expanding critical care infrastructure globally.
MDTBSXEWBDXTFXmedical devicescardiovascular disease